13F Pro

SEC Form 4 reporting owner

Hite Christopher

Hite Christopher has filed 15 Form 4 transactions reported between February 11, 2026 and September 22, 2026, as EVP & Chairman, Partnering, EVP & Vice Chairman of Royalty Pharma plc, a reporting owner of Kailera Therapeutics, Inc. and a reporting owner of Vera Therapeutics, Inc..

Name as filed: Hite Christopher

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$27.4M
9 lines
Companies
3
with Form 4 filings
Latest transaction
Sep 22, 2026
transaction date

Roles and reported holdings

  • RPRXRoyalty Pharma plc
    Feb 11, 2026 – Sep 22, 2026

    EVP & Chairman, Partnering, EVP & Vice Chairman

    Held directly23,200 sh as of Aug 19, 2026 · Form 4
    Held indirectly (latest line)270,401 sh as of Sep 22, 2026 · Form 4

    24 months: $27.4M sold

  • KLRAKailera Therapeutics, Inc.
    Apr 16, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • VERAVera Therapeutics, Inc.
    Mar 5, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 15 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 22, 2026RPRXEVP & Chairman, PartneringOpen-market saleCode S · indirect3,927$231K@ $58.93Form 4
Sep 22, 2026RPRXEVP & Chairman, PartneringOpen-market saleCode S · indirect96,073$5.6M@ $58.51Form 4
Aug 19, 2026RPRXEVP & Chairman, PartneringGiftCode G · direct16,800—Form 4
Aug 18, 2026RPRXEVP & Chairman, PartneringOpen-market saleCode S · indirect100,000$6.0M@ $59.97Form 4
Aug 5, 2026RPRXEVP & Chairman, PartneringGrant or awardCode A · indirect11,002—Form 4
Jun 30, 2026RPRXEVP & Chairman, PartneringOpen-market saleCode S · direct600$34K@ $57.09Form 4
Jun 30, 2026RPRXEVP & Chairman, PartneringOpen-market saleCode S · direct29,400$1.7M@ $56.44Form 4
Jun 30, 2026RPRXEVP & Chairman, PartneringOpen-market saleCode S · indirect2,554$146K@ $57.10Form 4
Jun 30, 2026RPRXEVP & Chairman, PartneringOpen-market saleCode S · indirect97,446$5.5M@ $56.50Form 4
Jun 23, 2026RPRXEVP & Chairman, PartneringOpen-market saleCode S · indirect117,592$6.4M@ $54.47Form 4
Jun 23, 2026RPRXEVP & Chairman, PartneringOpen-market saleCode S · indirect32,408$1.8M@ $54.11Form 4
May 6, 2026RPRXEVP & Vice ChairmanGrant or awardCode A · indirect24,263—Form 4
Apr 16, 2026KLRAGrant or awardCode A · direct38,300—Form 4
Mar 5, 2026VERAGrant or awardCode A · direct24,937—Form 4
Feb 11, 2026RPRXEVP & Vice ChairmanGrant or awardCode A · indirect26,626—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.